指南与共识产科母胎医学

母胎医学会指南推荐意见的循证证据评估

Assessment of evidence underlying guidelines by the Society for Maternal-Fetal Medicine.
指南 / 共识 · Am J Obstet Gynecol · 2020-08-21

该研究评估了母胎医学会采用GRADE系统制定的全部推荐意见,共纳入24份文件中的235条推荐。仅15%的推荐由高质量证据支持,其中97%被定为强推荐;中等和低质量证据支持的推荐分别有78%和68%被定为强推荐。结论提示高质量临床试验仍是产科优先事项,强推荐常基于证据质量以外的强度决定因素。

要点

  • 母胎医学会235条GRADE推荐中仅15%由高质量证据支持。
  • 高质量证据支持的推荐97%为强推荐,中等和低质量证据支持的推荐分别78%和68%为强推荐。
  • 推荐仅8%由随机试验支持,64%由汇总原始数据的文献支持。

核心结论

  • 母胎医学会采用GRADE系统制定的推荐中15%由高质量证据支持,提示精心设计的高质量临床试验仍是产科优先事项。
  • 强推荐常基于证据质量以外的GRADE强度决定因素作出。
  • 提高母胎医学会基于证据质量以外强度决定因素判定强推荐的透明度可能对临床医生有用。

研究设计与样本

  • 研究审查了母胎医学会出版物与指南网站的全部出版物,仅分析含GRADE推荐的文件。
  • 共纳入24份文件、235条GRADE推荐,按证据质量和推荐强度汇总比较。
  • 按推荐主题和类型分层比较,并汇总支持每条推荐的参考文献类型。
  • 比较了母胎医学会与美国妇产科医师学会联合制定的推荐与母胎医学会单独制定的推荐。

主要发现

  • 35条(15%)推荐由高质量证据支持,其中34条(97%)为强推荐。
  • 中等质量证据支持的推荐(n=102)中78%为强推荐,低质量证据支持的推荐(n=75)中68%为强推荐。
  • 推荐由随机试验支持的比例为8%,由汇总原始数据的文献(如Meta分析、综述、既往指南)支持的比例为64%。
  • 证据质量评级较高的推荐更可能由汇总原始数据的文献支持:高质量69%、中等质量74%、低质量49%。
  • 母胎医学会与美国妇产科医师学会联合制定的推荐较母胎医学会单独制定的推荐有更高比例由高质量证据支持(26% vs 9%)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Society for Maternal-Fetal Medicine, sometimes together with the American College of Obstetricians and Gynecologists, publishes guidelines utilizing the Grading of Recommendations, Assessment, Development, and Evaluation system to rate the quality of evidence and assign the strength of its recommendations. The strength of recommendations is determined by the quality of evidence and 3 other strength determinants that are defined in this system. OBJECTIVE: This study aimed to assess all recommendations by the Society for Maternal-Fetal Medicine assessed by the Grading of Recommendations, Assessment, Development, and Evaluation system, determine the quality of evidence supporting them, evaluate the relationship between quality of evidence and strength of recommendations, and determine the extent to which the other 3 strength determinants were employed to assign recommendation strength. STUDY DESIGN: All publications from the Society for Maternal-Fetal Medicine Publications and Guidelines website were reviewed, but only the ones with Grading of Recommendations, Assessment, Development, and Evaluation recommendations were analyzed. These were aggregated by their rating for quality of evidence and strength. Quality and strength were first compared across all recommendations. Subsequently, they were compared with stratification by recommendation topic and type (eg, interventions, counseling, screening, and diagnosis). References supporting each recommendation were also summarized by type (eg, randomized trial, retrospective study). The quality of evidence for each recommendation was then compared with the supporting reference types. Other characteristics that may contribute to strength were also evaluated. Finally, we compared recommendations authored jointly by the Society for Maternal-Fetal Medicine and the American College of Obstetricians and Gynecologists with those by the Society for Maternal-Fetal Medicine alone. RESULTS: The Society for Maternal-Fetal Medicine published 24 documents containing 235 recommendations assessed by the Grading of Recommendations, Assessment, Development, and Evaluation system. There were 35 (15%) recommendations supported by high-quality evidence; 34 (97%) were determined to be strong. Recommendations supported by moderate-quality (n=102) and low-quality (n=75) evidence were also rated as strong in 78% and 68% of cases, respectively. Recommendations were supported by randomized trials 8% of the time and references that summarize primary data (eg, meta-analyses, reviews, previous guidelines) 64% of the time. Recommendations with higher quality evidence ratings were more likely to be supported by references that summarize primary data (69% high-quality, 74% moderate-quality, 49% low-quality). Topics with recommendations authored jointly by the Society for Maternal-Fetal Medicine and the American College of Obstetricians and Gynecologists were supported by higher quality evidence than those by the Society for Maternal-Fetal Medicine alone (high quality, 26% vs 9%, respectively). CONCLUSION: Recommendations by the Society for Maternal-Fetal Medicine assessed by the Grading of Recommendations, Assessment, Development, and Evaluation system were supported by high-quality evidence in 15% of cases. This suggests that well-designed, high-quality clinical trials remain a priority in obstetrics. Strong recommendations were often made on the basis of Grading of Recommendations, Assessment, Development, and Evaluation strength determinants other than quality of evidence. Increased transparency of the Society for Maternal-Fetal Medicine's determination of strong recommendations based on strength determinants other than quality of the evidence may be useful to practicing clinicians.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Brock CO, Blackwell SC, Chauhan SP, et al. Assessment of evidence underlying guidelines by the Society for Maternal-Fetal Medicine. Am J Obstet Gynecol. 2020. PMID: 32835718. doi:10.1016/j.ajog.2020.08.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。